Yau Tsz-Kok, Lee Anne Wing-Mui, Wong Dominique Hiu-Ming, Yeung Rebecca Mei-Wan, Chan Elian Wing-Kin, Ng Wai-Tong, Tong Macy, Soong Inda Sung
Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, 3 Lok Man Road, Chai Wan, Hong Kong.
Head Neck. 2006 Oct;28(10):880-7. doi: 10.1002/hed.20421.
The purpose of this study was to evaluate the efficacy and toxicity of cisplatin plus gemcitabine as induction chemotherapy in advanced nasopharyngeal carcinoma (NPC).
Thirty-seven patients with stage IV(A-B) NPC were treated with 3 cycles of cisplatin plus gemcitabine (cisplatin 80 mg/m(2) on day 1; gemcitabine 1250 mg/m(2) on days 1 and 8) 3-weekly as induction chemotherapy, followed by another 3 cycles of concurrent cisplatin (100 mg/m(2) on day 1) 3-weekly with accelerated radiotherapy (RT) at 70 Gy in 2-Gy fractions, 6 daily fractions per week.
The overall response rate to induction chemotherapy was > 90%, and side effects other than uncomplicated hematologic toxicities were uncommon. All patients completed RT, with 92% receiving > or = 5 cycles of chemotherapy. At a median follow-up of 2.9 years, the 3-year overall survival (OS) and disease-free survival (DFS) rates were 76% and 63%, respectively.
Cisplatin plus gemcitabine is a well-tolerated, effective, and convenient induction chemotherapy regimen and warrants further studies to confirm its benefit in advanced NPC.
本研究旨在评估顺铂联合吉西他滨作为晚期鼻咽癌（NPC）诱导化疗的疗效和毒性。
37例IV（A - B）期NPC患者接受3周期顺铂联合吉西他滨诱导化疗（顺铂80mg/m²，第1天；吉西他滨1250mg/m²，第1天和第8天），每3周1次，随后再接受3周期顺铂同步化疗（第1天100mg/m²），同时进行加速放疗（RT），总剂量70Gy，每次2Gy，每周6次，每天1次。
诱导化疗的总缓解率>90%，除单纯血液学毒性外的副作用不常见。所有患者均完成放疗，92%的患者接受了≥5周期化疗。中位随访2.9年时，3年总生存率（OS）和无病生存率（DFS）分别为76%和63%。
顺铂联合吉西他滨是一种耐受性良好、有效且方便的诱导化疗方案，值得进一步研究以证实其对晚期NPC的益处。
